Recent advances in the field of tubulin polymerization inhibitors

Expert Review of Anticancer Therapy

Volumn 2, Issue 6, 2002, Pages 695-708

  Prinz, Helge ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

A 105972; COBRA; Curacin A; D 24851; Indanocine; Methoxyestradiol; Multidrug resistance; Phenylahistin; SPIKET; Vinflunine

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 METHOXYESTRADIOL; ALKYLATING AGENT; ANTIMITOTIC AGENT; AURISTATIN PE; CHALCONE DERIVATIVE; COLCHICINE; COMBRETASTATIN; CURACIN A; CYTOTOXIC AGENT; DOCETAXEL; DOLASTATIN 10; GLYCOPROTEIN P; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; NAVELBINE; OXAZOLINE DERIVATIVE; PACLITAXEL; PODOPHYLLOTOXIN; PRODRUG; STILBENE DERIVATIVE; SULFONAMIDE; SULFONIC ACID DERIVATIVE; TAXOID; TUBULIN; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; ANTINEOPLASTIC AGENT; BIBENZYL DERIVATIVE; BIOLOGICAL FACTOR; TUBULIN MODULATOR;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG DESIGN; DRUG ISOLATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MICROTUBULE ASSEMBLY; MOLECULAR WEIGHT; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; REVIEW; STRUCTURE ACTIVITY RELATION; BIOSYNTHESIS; DRUG EFFECT; METABOLISM; NEOPLASM; PROTEIN BINDING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIBENZYLS; BIOLOGICAL FACTORS; DRUG DESIGN; HUMANS; NEOPLASMS; PROTEIN BINDING; STILBENES; TUBULIN; TUBULIN MODULATORS;

EID: 0036902919     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.2.6.695     Document Type: Review

References (62)

1. Jordan MA, Hadfield JA, Lawrence NJ, McGown AT. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle Med. Res. Rev. 18, 259-296 (1998).
2. Li Q, Sham HI, Rosenberg SH. Antimitotic agents. Ann. Rep. Med. Chem. 34, 139-148 (1999).
3. von Angerer E. New inhibitors of tubulin polymerisation. Exp. Opin. Ther. Patents 9, 1069-1081 (1999).
4. Jiménez-Barbero J, Amat-Guerri F, Snyder JP. The solid state, solution and tubulin-bound conformations of agents that promote microtubule stabilization. Curr. Med. Chem. AntiCancer Agents 2, 91-122 (2002).
5. Rowinsky EK, Donehower RC. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol. Ther. 52, 35-84 (1992).
6. Dumontet C, Sikic BI, Mechanism of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J. Clin. Oncol. 3, 1061-1070 (1999).
7. Fardel O, Lecureur V, Guillouzo A. The P-glycoprotein multidrug transporter. Gen. Pharmcol. 27, 1283-1291 (1996).
8. Cole SP, Deeley RG. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays 20, 931-940 (1998).
9. Hussain M, Wozniak AJ, Edelstein MB. Neurotoxicity of antineoplastic agents. Crit. Rev. Oncol. Hematol. 14, 61-75 (1993).
10. Windebank AJ. Chemotherapeutic neuropathy. Curr. Opin. Neurol. 12, 565-571 (1999).
11. Hastie SB. Interactions of colchicine with tubulin. Pharmacol. Ther. 51, 377-401 (1991).
12. Nogales E, Wolf SG, Downing KH. Structure of the α/β tubulin dimer by electron crystallography. Nature. 391, 199-203 (1998).
13. Uckun FM, Mao C, Vassilev AO, Huang H, Jan ST. Structure-based design of a novel synthetic spiroketal pyran as a pharmacophore for the marine natural product spongistatin 1. Bioorg. Med. Chem. Lett. 10, 541-545 (2000).
14. Snyder JP, Nettles JH, Cornett B, Downing KH, Nogales E. The binding conformation of taxol in β-tubulin: a model based on electron crystallographic density. Proc. Natl. Acad. Sci. USA 98, 5312-5316 (2001).
15. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 45, 209-211 (1989).
16. Pettit GR, Singh SB, Boyd MR et al. Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5 and A-6. J. Med. Chem. 38, 1666-1672 (1995).
17. Pettit GR, Rhodes MR. Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug. Anticancer Drug Des. 13, 183-191 (1998).
18. Tozer GM, Prise VE, Wilson J et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. 59, 1626-1634 (1999).
19. Gwaltney SL,Imade HM, Barr KJ et al. Novel sulfonate analogues of combretastatin A-4: potent antimitotic agents. Bioorg. Med. Chem. Lett. 11, 871-874 (2001).
20. Ducki S, Forrest R, Hadfield JA et al. Potent antimitotic and cell growth inhibitory properties of substituted chalcones. Bioorg. Med. Chem. Lett. 8, 1051-1056 (1998).
21. Lawrence NJ, McGown AT, Ducki S, Hadfield JA. The interaction of chalcones with tubulin. Anti-Cancer Drug Des. 15, 135-141 (2000).
22. Ohsumi K, Hatanaka T, Fujita K et al. Synthesis and antitumor activity of cis-restricted combretastatins: five membered heterocyclic analogues. Bioorg. Med. Chem. Lett. 8, 3153-3158 (1998).
23. Wu-Wong JR, Alder JD, Alder L et al. Identification and characterization of A-105972, an antineoplastic agent. Cancer Res. 61(4), 1486-1492 (2001).
24. Tahir SK, Han EKH, Credo B et al. A-204197, a new tubulin binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. Cancer Res. 61(14), 5480-5485 (2001).
25. Li Q, Woods KW, Claiborne A et al. Synthesis and biological evaluation of 2-indolyloxazolines as a new class of tubulin polymerization inhibitors. Discovery of A-289099 as an orally active antitumor agent. Bioorg. Med. Chem. Lett. 12, 465-469 (2002).
26. Wang L, Woods KW, Li Q et al. Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumour activity evaluation. J. Med. Chem. 45, 1697-1711(2002).
27. Pinney KG, Bounds AD, Dingeman KM et al. A new anti-tubulin agent containing the benzo [b] thiophene ring system. Bioorg. Med. Chem. Lett. 9, 1081-1086 (1999).
28. Flynn BL, Flynn GP, Hamel E, Jung MK. The synthesis and tubulin binding activity of thiophene-based analogues of combretastatin A-4. Bioorg. Med. Chem. Lett. 11, 2341-2343 (2001).
29. Bacher G, Nickel B, Emig P et al D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficiacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. Cancer Res. 61, 392-399 (2001).
30. Gastpar R, Goldbrunner M, Marko D, von Angerer E. Methoxy-substituted 3-formyl-2-phenylindoles inhibit tubulin polymerization. J. Med. Chem. 41, 4965-4972 (1998).
31. Medarde M, Ramos AC, Caballero E et al. Synthesis and anti-neoplastic activity of combretastatin analogues: heterocombretastatins. Eur. J. Med. Chem. 33, 71-77 (1998).
32. Medarde M, Ramos AC, Caballero E et al. Synthesis and pharmacological activity of diarylindole derivatives. Cytotoxic agents based on combretastatins. Bioorg. Med. Chem. Lett. 9, 2303-2308 (1999).
33. Mahboobi S, Pongratz H, Hufsky H et al. Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents. J. Med. Chem. 44, 4535-4553 (2001).
34. Gourley M, Williamson JS. Angiogenesis: New targets for the development of anticancer chemotherapies. Curr. Pharm. Des. 6, 417-439 (2000).
35. Leoni LM, Hamel E, Genini D et al. Indanocine, a microtubule-binding indanone and a selective inducer of apoptosis in multidrug-resistant cancer cells. J. Natl. Cancer Inst. 92, 217-222 (2000).
36. Shih H, Deng L, Carrera CJ, Adachi S, Cottam HB, Carson DA. Rational design, synthesis and structure-activity relationships of antitumor (E)-2-benzylidene-1-tetralones and (E)-2-benzylidene-1 indanones. Bioorg. Med. Chem. Lett. 10, 487-490 (2000).
37. Uckun FM, Mao C, Jan ST et al. SPIKET and COBRA compounds as novel tubulin modulators with potent anticancer activity. Curr. Opin. Investig. Drugs. 1, 252-256 (2000).
38. Uckun FM, Mao C, Jan ST et al. Spongistatins as tubulin targeting agents. Curr. Pharm. Des. 7, 1291-1296 (2001).
39. Pettit GR, Cichacz ZA, Gao F et al. Isolation and structure of spongistatin 1. J. Org. Chem. 58, 1302-1304 (1993).
40. Uckun FM, Mao C, Vassilev AO, Navara CS, Narla RKS, Jan ST. A rationally designed anticancer drug targeting a unique binding cavity of tubulin. Bioorg. Med. Chem. Lett. 10, 1015-1018 (2000).
41. Poncet J. The dolastatins, a family of promising antineoplastic agents. Curr. Pharm. Design 5, 139-162 (1999).
42. Bai R, Taylor GF, Schmidt JM et al. Interaction of dolastatin 10 with tubulin: induction of aggregation and binding and dissociation reactions. Mol. Pharmacol. 47, 965-976 (1995).
43. Fotsis T, Zhang, Y, Pepper MS et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368, 237-239 (1994).
44. Schumacher G, Kataoka M, Roth JA, Mukhopadhyay T. Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin. Cancer Res. 5, 493-4499 (1999).
45. Cushman M, He HM, Katzenellenbogen JA et al. Synthesis of analogs of 2-methoxyestradiol with enhanced inhibitory effects on tubulin polymerization and cancer cell growth. J. Med. Chem. 40, 2323-2334 (1997).
46. Wang Z, Yang D, Mohanakrishnan AK et al. Synthesis of B-ring homologated estradiol analogues that modulate tubulin polymerization and microtubule stability. J. Med. Chem. 43, 2419-2429 (2000).
47. Verdier-Pinard P, Wang Z, Mohanakrishnan AK, Cushman M, Hamel E. A steroid derivative with paclitaxel-like effects on tubulin polymerization. Mol. Pharmacol. 57, 568-575 (2000).
48. Gerwick WH, Proteau PJ, Nagle DG, Hamel E, Blokhin A, Slate D. Structure of curacin A, a novel antimitotic, antiproliferative, and brine shrimp toxic natural product from the marine cyanobacterium Lyngbia majuscula. J. Org. Chem. 59,1243-1245 (1994).
49. Blokhin AV, Yoo HD, Geralds RS, Nagle DG, Gerwick WH, Hamel E. Characterization of the interaction of the marine cyanobacterial natural product curacin A with the colchicine site of tubulin and initial srructure-activity studies with analogues. Mol. Pharmacol. 48, 523-531 (1995).
50. Verdier-Pinard P, Sitachitta M, Rossi JV, Sackett DL, Gerwick WH, Hamel E. Biosynthesis and radiolabeled curacin A and its rapid and apparently irreversible binding to the colchicine site of tubulin. Arch. Biochem Biophys. 370, 51-58 (1999).
51. Kanoh K, Kohno S, Katada J, Takahashi J, Uno I. (-)-Phenylahistin arrests cells in mitosis by inhibiting tubulin polymerization. J. Antibiot. (Tokyo) 52, 134-141 (1999).
52. Kanoh K, Kohno S, Katada J, Takahashi J, Uno I, Hayashi Y. Synthesis and biological activities of phenylahistin derivatives. Bioorg. Med. Chem. 7,1451-1457 (1999).
53. Legault J, Gaulin JF, Mounetou E et al. Microtubule disruption induced in vivo by alkylation of β-tubulin by 1-aryl-3-(2-chloroethyl)ureas, a novel class of soft alkylting agents. Cancer Res. 60, 985-992 (2000).
54. Medina JC, Shan B, Beckmann H et al. Novel antineoplastic agents with efficacy against multidrug resistant tumor cells. Bioorg. Med. Chem. Lett. 8, 2653-2656 (1998).
55. Shan B, Medina JC, Santha E et al. Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proc. Natl Acad Sci. US4 96, 5686-5691 (1999).
56. Combeau C, Provost J, Lancelin F et al. RPR112378 and RPR115781: two representatives of a new family of microtubule assembly inhibitors. Mol. Pharmacol 57, 553-563 (2000).
57. Hill BT Vinflunine, a second generation novel vinca alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockers. Curr. Pharm. Des. 7, 1199-1212 (2001).
58. Fumoleau P, Raymond E, Bennouna J et al. Phase I trial of vinflunine (L0070) a novel fluorinated vinca alkaloid in patients (pts) with advanced solid malignancies: final results. Proc. Am. Assoc. Cancer Res. 42, 834 (2001).
59. Ngan VK, Bellman K, Panda D, Hill BT, Jordan MA, Wilson L. Novel action of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res. 60, 5045-5051 (2000).
60. Etiévant C, Kruczynski A, Barret JM, Tait AS, Kavallaris M, Hill BT. Markedly diminished drug resistance-inducing properties of vinflunine (20′,20′-difluoro-3′,4′-dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro. Cancer Chemother. Pharmacol. 48, 62-70 (2001).
61. Hill BT, Fiebig HH, Waud WR, Poupo MF, Colpaert F, Kruczynski A. Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur. J. Cancer 35, 512-520 (1999).
62. Holwell SE, Hill BT, Bibby MC. Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. Br. J. Cancer. 84, 290-295 (2001).